The Sijbrandij Foundation has introduced a pilot initiative intended to help cancer patients and families navigate diagnostic tests, treatment research, clinical services and suppliers that may sit outside a single care team's immediate view. The program, called Future of Cancer Care Today, or FCCT, describes itself as a non-clinical information and decision-support layer rather than a medical provider.
FCCT says its PhD-led team prepares case-relevant playbooks and curates resources so families can discuss a broader set of possibilities with their clinicians. Its stated premise is that cancer science, diagnostics and trials change faster than any one team can continuously survey, especially when standard treatment options are exhausted. The service says it may surface options beyond standard care but does not diagnose, prescribe, select treatments or replace physicians.
That boundary is central to evaluating the initiative. The foundation says all care decisions remain with patients and their doctors, and that materials created with artificial-intelligence assistance should be reviewed by medical professionals before they influence care. Its website also says that inclusion in its supplier directory does not amount to endorsement, certification or referral. Patients are told to verify details directly and discuss next steps with their clinical team.
The directory spans several categories of precision oncology. It lists services for preserving tumour tissue, molecular profiling, laboratory drug-response testing and monitoring disease through circulating tumour DNA or other signals. Availability and ordering routes vary. Some services are described as patient-accessible, while many require a physician order or referral through participating hospitals. Geographic reach also differs across the United States, Europe and other regions.
FCCT is a pilot of the foundation and is led by Poornima Parameswaran. The organization says its approach was informed by Sid Sijbrandij's cancer experience as well as those of other patients and families. The published material does not establish that every listed test or service is appropriate for a particular cancer, nor does it provide comparative clinical evidence for the directory as a whole.
The initiative enters a difficult information environment. A long catalogue can help families discover questions they did not know to ask, but it can also be hard to distinguish experimental, commercially available and clinically validated options. FCCT's own disclaimers therefore matter: a resource list is a starting point for discussion, not a treatment plan.
As the pilot develops, useful measures of its value would include how it selects and updates resources, handles conflicts and patient data, represents the strength of evidence, and integrates with oncology teams. For now, the project is best understood as structured research assistance designed to complement professional cancer care, with medical judgment remaining outside its remit.
